Cannordic A/S

Cannordic A/S specializes in topical pain relief products, including medicated patches (such as Rhyzax Schmerzpflaster and CANNASEN® Pain Patch), pain and arthritis gels (like CANNASEN® Pain & Arthritis Gel), and wound gels (e.g., CANNASEN® Wound Gel). The company also produces nasal sprays and nasal protect gels, such as CANNASEN® Nasal Night Spray and CANNASEN® Nasal Protect Gel, which are designed for respiratory support. These devices are formulated for direct application to the skin or nasal passages to address pain, inflammation, or wound care.

Cannordic A/S is based in Denmark (DK). The company focuses on developing and manufacturing topical medical devices aimed at pain relief and wound care, including products like CBD-based patches and gels, as well as non-CBD alternatives. Its portfolio targets conditions such as chronic pain, arthritis, and respiratory discomfort, with formulations designed for direct application to the affected areas.

Cannordic A/S’s devices are listed in the EUDAMED database, which is the European Union’s medical device registry. This registry is used to track devices that comply with EU Medical Device Regulations (MDR) or In Vitro Diagnostic Regulation (IVDR). Since these devices are classified as Class I, they are subject to mandatory registration under EU requirements, ensuring transparency and traceability for healthcare professionals and authorities.

Cannordic A/S’s devices fall under Class I classification according to EU Medical Device Regulations. This classification applies to low-risk devices like topical pain patches, gels, and nasal sprays, which pose minimal risk to patients when used as intended. Class I devices typically require compliance with basic safety and performance requirements but do not undergo the same stringent clinical evaluations as higher-risk classes (e.g., Class IIa, IIb, or III). The classification ensures these products meet essential safety standards while streamlining regulatory oversight.